Market Cap : 3.87 B | Enterprise Value : 4.16 B | PE Ratio : At Loss | PB Ratio : 7.49 |
---|
NAS:GH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Operating Margin % is calculated as Operating Income divided by its Revenue. Guardant Health's Operating Income for the three months ended in Mar. 2022 was $-123.3 Mil. Guardant Health's Revenue for the three months ended in Mar. 2022 was $96.1 Mil. Therefore, Guardant Health's Operating Margin % for the quarter that ended in Mar. 2022 was -128.34%.
Good Sign:
Guardant Health Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Guardant Health's Operating Margin % or its related term are showing as below:
Guardant Health's 5-Year Average Operating Margin % Growth Rate was 13.10% per year.
Guardant Health's Operating Income for the three months ended in Mar. 2022 was $-123.3 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 was $-426.5 Mil.
The historical data trend for Guardant Health's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Guardant Health's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Guardant Health's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as
Operating Margin % | = | Operating Income (A: Dec. 2021 ) | / | Revenue (A: Dec. 2021 ) |
= | -411.001 | / | 373.653 | |
= | -110.00 % |
Guardant Health's Operating Margin % for the quarter that ended in Mar. 2022 is calculated as
Operating Margin % | = | Operating Income (Q: Mar. 2022 ) | / | Revenue (Q: Mar. 2022 ) |
= | -123.338 | / | 96.099 | |
= | -128.34 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But NokiaÂ’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of Guardant Health's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Talasaz Amirali | director, officer: Chairman, President and COO | 18 ISABELLA AVENUE ATHERTON CA 94027 |
Kaul Samir | director | C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
Meresman Stanley J | director | 2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
Svf Bluebird (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Svf Enterprise (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Sb Investment Advisers (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET LONDON X0 W1K 3JP |
Softbank Vision Fund (aiv M1) L.p. | 10 percent owner | 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Clark Ian T | director | SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Eltoukhy Helmy | director, officer: Chief Executive Officer | 2 BARRY LANE ATHERTON CA 94027 |
Bertocci Derek A | officer: Chief Financial Officer | 3070 ORCHARD DRIVE SAN JOSE CA 95134 |
Saia John G. | officer: See Remarks | C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
Gadde Vijaya | director | C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
Jallal Bahija | director | 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
Nishar Dipchand | director | C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
From GuruFocus
Other Sources
By Zacks 2021-11-03
By Zacks 2022-01-27
By Seekingalpha 2022-01-24
By Zacks 2021-08-05
By tipranks.com 2022-04-05
By Zacks 2022-02-23
By Zacks 2021-11-04
By tipranks.com 2022-03-10
By Seekingalpha 2021-11-04
By tipranks.com 2022-02-16
By Fool 2022-01-12
By Zacks 2021-07-19
By Zacks 2022-01-28
By Zacks 2022-01-26